mVacciNation

GSK’s mVacciNation programme is a mobile technology-based supply chain management capacity building programme, aiming to increase childhood immunisation in Mozambique.

Summary  

  • What: GSK has scaled up its mVacciNation programme since its launch in 2014.
  • Details: The programme uses mobile technology to improve vaccine stock management and tracking of vaccination visits.
  • Objective: GSK is aiming to help increase childhood immunisation in Mozambique.
  • Context: The programme’s partners include the Mozambique Ministry of Health, Vodafone, Gavi and USAID.

In Nampula, Mozambique, a healthworker uses GSK’s mVacciNation mobile technology to improve patient-record keeping.

Looking closer

GSK has scaled up its mVacciNation programme (launched in 2014 and recognised as innovation in the Access to Medicine Index 2014). Through the programme, GSK is continuing to test whether mobile technologies can help increase childhood immunisation in Mozambique, in partnership with the Ministry of Health, Vodafone, Gavi and USAID. The programme uses mobile technology to support health workers, facilitate record keeping, and improve vaccine stock management. It also allows health workers to register infants and their caregivers, to remind caregivers of vaccination appointments and record the infant’s vaccination history. This encourages completion of the full vaccination schedule.

The pilot is being independently evaluated as a randomised control trial by the Abdul Latif Jameel Poverty Action Lab (J-PAL) Africa research unit, based at the University of Cape Town, and the National Institute of Health in Mozambique. The impact evaluation will measure the impact of the mVacciNation programme on vaccination rates and stock management, as well as its cost-effectiveness and impact on health system processes.

The programme was scaled-up in the period of analysis for the Access to Medicine Index 2016 (from 17 to 76 participating facilities in December 2015). Pending the outcomes of the independent evaluation, GSK has indicated interest in further replicating the mVacciNation model in other areas of Mozambique and in other countries in sub-Saharan Africa.

GSK’s mVacciNation pilot demonstrates innovation in using mobile technology to address barriers to vaccination in a low-resource setting at multiple levels: from stock and supply chain management to tracking of vaccination visits.

Sign up to receive updates about our work.